Abstract
INTRODUCTION: Alzheimer's disease (AD), a neurodegenerative disorder closely associated with aging, is characterized by progressive cognitive decline and is a leading cause of dementia worldwide. Oxidative stress plays a pivotal role in AD's pathophysiology, contributing to amyloid-beta accumulation, neurofibrillary tangles, and neuronal damage. AIM: This study investigates the potential of F2-isoprostanes and Presenilin-1 (PSEN1) as biomarkers for oxidative stress and their association with clinically diagnosed Alzheimer's disease. MATERIALS AND METHODS: A comparative cross-sectional study will be conducted, enrolling 50 AD patients and 50 age-matched healthy controls from the Vidarbha region. Serum levels of F2-isoprostanes and PSEN1 will be measured using advanced analytical techniques, and their correlation with AD progression will be analyzed statistically. RESULTS AND CONCLUSION: The findings are expected to provide insights into the diagnostic and prognostic value of these markers, offering potential avenues for early detection and therapeutic intervention in Alzheimer's disease.